Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   41189   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2015-000966-72
    Sponsor's Protocol Code Number:221AD301
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2015-06-03
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-000966-72
    A.3Full title of the trial
    A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease
    Studio multicentrico di Fase 3, randomizzato, in doppio cieco, controllato con placebo, a gruppi paralleli per valutare l’efficacia e la sicurezza di Aducanumab (BIIB037) in soggetti con malattia di Alzheimer precoce
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    221AD301 Phase 3 Study of Aducanumab in Early Alzheimer's Disease
    221AD301 Studio di Fase 3 con Aducanumab nella Malattia di Alzheimer precoce
    A.4.1Sponsor's protocol code number221AD301
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBiogen Idec Research Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiogen Idec Research Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBiogen Idec Research Limited
    B.5.2Functional name of contact pointN/A
    B.5.3 Address:
    B.5.3.1Street AddressInnovation House, 70 Norden Road
    B.5.3.2Town/ cityMaidenhead
    B.5.3.3Post codeSL6 4AY
    B.5.3.4CountryUnited Kingdom
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAducanumab
    D.3.2Product code BIIB037
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAducanumab
    D.3.9.1CAS number N/A
    D.3.9.2Current sponsor codeBIIB037
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D. medicinal product typerecombinant monoclonal antibody
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection/infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Early Alzheimer's Disease
    Malattia di Alzheimer precoce
    E.1.1.1Medical condition in easily understood language
    Early Alzheimer's Disease
    Malattia di Alzheimer precoce
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level LLT
    E.1.2Classification code 10001896
    E.1.2Term Alzheimer's disease
    E.1.2System Organ Class 100000004852
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Placebo-controlled period:
    To evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo in subjects with early AD.

    Long-term Extension:
    To evaluate the long-term safety and tolerability profile of aducanumab in subjects with early AD.

    To evaluate the long-term efficacy of aducanumab treatment as measured by clinical, radiological, and additional assessments reported by the subject and informant/care partner.
    periodo dello studio controllato con placebo:
    valutare l’efficacia di dosi mensili di aducanumab nel rallentare il deterioramento cognitivo e funzionale misurato in termini di variazioni nel punteggio CDR-SB rispetto al placebo in soggetti con AD precoce

    estensione a lungo termine con dose in cieco:
    valutare il profilo della sicurezza e della tollerabilità a lungo termine di aducanumab in soggetti con AD precoce
    valutare l’efficacia a lungo termine del trattamento con aducanumab misurato mediante valutazioni cliniche, radiologiche e altre valutazioni riferite dal soggetto e dall’informatore/assistente.
    E.2.2Secondary objectives of the trial
    To assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by the MMSE.

    To assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by ADAS-Cog 13.

    To assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by ADCS-ADL-MCI.

    Valutare l’efficacia di dosi mensili di aducanumab rispetto al placebo sulla progressione clinica misurata in termini di MMSE.

    Valutare l’efficacia di dosi mensili di aducanumab rispetto al placebo sulla progressione clinica misurata in termini di ADAS-Gog 13.

    Valutare l’efficacia di dosi mensili di aducanumab rispetto al placebo sulla progressione clinica misurata in termini di ADCS-ADL-MCI.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Key Inclusion Criteria:
    - Must meet all of the following clinical criteria for MCI due to AD or mild
    AD and must have:
    - A Clinical Dementia Rating (CDR)-Global Score of 0.5.
    - A Repeatable Battery for Assessment of Neuropsychological Status (RBANS) score of 85 or lower indicative of objective cognitive impairment
    - An MMSE score between 24 and 30 (inclusive)
    - Must have a positive amyloid Positron Emission Tomography (PET)
    - Must consent to apolipoprotein E (ApoE) genotyping
    - Must have stable symptomatic AD medications
    - Must have a reliable informant or caregiver

    LTE specific Criteria at week 78:
    - Must have completed the placebo-controlled period of the study.
    - MMSE score > 15 at the Week 78 Visit.
    - Must (or the subject’s legally authorized representative) understand the purpose and risks of the study and provide signed consent (or assent)
    - Apart from a clinical diagnosis of AD, subject must be in good health as determined by the Investigator, based on medical history.
    - Must have the ability to comply with procedures for protocol-related tests.
    - Must have reliable informant or caregiver

    NOTE: Other protocol defined Inclusion criteria may apply
    Criteri di Inclusione Chiave:
    - i soggetti devono soddisfare i seguenti criteri clinici per deterioramento cognitivo lieve dovuto a Malattia di Alzheimer (AD) o AD lieve e devono avere:
    - un punteggio di CDR di 0.5
    - un punteggio di RBANS di 85 o minore indicativo di deterioramento cognitivo oggettivo
    - un punteggio di MMSE tra 24 e 30 (Incluso)
    - devono risultare positivi all’amiloidosi misurata mediante tomografia ad emissione di positroni dell’amiloide
    - devono acconsentire alla genotipizzazione dell'Apolipoproteina E (ApoE)
    - devono assumere farmaci stabilmente per AD sintomatica
    - devono avere un informatore/assistente affidabile

    Criteri per periodo di estensione a lungo termine alla settimana 78:
    - devono aver completato il periodo dello studio controllato dal placebo
    - punteggio MMSE > 15 alla Visita della Settimana 78
    - il soggetto (o rappresentante legale del soggetto) deve capire lo scopo e i rischi dello studio e fornire il consenso firmato (o assenso)
    - Oltre ad una diagnosi clinica di AD, il soggetto deve essere in buona salute, come determinato dallo sperimentatore , sulla base dell'anamnesi medica.
    - Deve avere la capacità di rispettare le procedure e i tests previsti dal protocollo .
    - Deve avere un informatore/assistente affidabile

    NOTA : Potrebbero essere applicate altre protocollo definito criteri di inclusione
    E.4Principal exclusion criteria
    Key Exclusion Criteria:
    - Any medical or neurological condition (other than Alzheimer's Disease)
    that might be a contributing cause of the subject's cognitive impairment
    - Have had a stroke or Transient Ischemic Attack (TIA) or unexplained
    loss of consciousness in the past 1 year
    - Clinically significant psychiatric illness in past 6 months
    - History of unstable angina, myocardial infarction, chronic heart failure,
    or clinical significant conduction abnormalities within 1 year prior to Screening
    - Indication of impaired renal or liver function
    - Have human immunodeficiency virus (HIV) infection
    - Have a significant systematic illness or infection in past 30 days
    - Relevant brain haemorrhage, bleeding disorder and cardiovascular abnormalities
    - Any contraindications to brain magnetic resonance imaging (MRI) or PET scans
    - Alcohol or substance abuse in past 1 year
    - Taking blood thinners (except for aspirin at a prophylactic dose or less)
    - Use of AD medications at doses that have not been stable for at least 8 weeks prior to Screening Visit 1

    Subjects will be excluded from entering the LTE if at Week 78 they have:
    - any medical or psychiatric contraindication or clinically significant abnormality that, in the opinion of the Investigator, will substantially increase the risk associated with the subject's participation in the study.

    NOTE: Other protocol defined Exclusion criteria may apply
    Criteri di esclusione principali:
    - Qualsiasi condizione medica o neurologica (diverse dalla malattia di Alzheimer)
    che potrebbe essere una concausa del decadimento cognitivo del soggetto
    - Ha avuto un ictus o attacco ischemico transitorio (TIA) o inspiegata perdita di coscienza nel precedente 1 anno
    - Malattia psichiatrica clinicamente significativa negli ultimi 6 mesi
    - una storia di angina instabile, infarto del miocardio, insufficienza cardiaca cronica, o anomalie di conduzione clinicamente significative entro 1 anno prima dello screening
    - indicazione di funzionalità renale o epatica compromessa
    - Avere virus dell'immunodeficienza umana (HIV)
    - Avere una malattia sistematica significativa o infezione negli ultimi 30 giorni
    - Rilevante emorragia cerebrale,disordini nel sanguinamento e anomalie cardiovascolari
    - Eventuali controindicazioni ad effettuare la risonanza magnetica del cervello(MRI) o PET
    - Alcool o abuso di sostanze nell'anno passato
    - Assunzione di anticoagulanti (ad eccezione di aspirina in una dose profilattica o a una dose minore)
    - Uso di farmaci AD a dosi non stabili per almeno 8 settimane prima della visita 1 di screening 1

    I soggetti saranno esclusi ad entrare nel LTE se alla settimana 78 hanno:
    - Qualsiasi controindicazione medica o psichiatrica o anomalia clinicamente significativa che, a giudizio dello sperimentatore, aumenterà notevolmente il rischio associato alla partecipazione del soggetto nello studio.

    NOTA: Potrebbero essere applicati altri criteri di esclusione definiti dal protocollo
    E.5 End points
    E.5.1Primary end point(s)
    Primary endpoint:
    Change from baseline in CDR-SB score at Week 78.

    LTE period endpoints:
    The incidence of AEs and/SAEs; brain MRI findings (including the incidence of ARIA-E and ARIA-H); and the incidence of anti-aducanumab antibodies in serum over the placebo-controlled and LTE periods of the study.
    Change in the following measures over the placebo-controlled and LTE periods of the study:
    CDR-SB score.
    MMSE score.
    ADAS-Cog 13 score.
    ADCS-ADL-MCI score.
    Amyloid PET signal (in a subset of subjects).
    Whole brain volume, hippocampal volume, ventricular volume, and cortical gray matter volume measured by MRI.
    Functional connectivity as measured by tf-fMRI (where available).
    Cerebral blood flow as measured by ASL-MRI (where available).
    Disease-related biomarker levels in CSF which will include, but are not limited to, amyloid and tau proteins (in a subset of subjects).
    Disease-related biomarker levels in blood which may include, but are not limited to, amyloid and tau proteins.
    NPI-10 total score.
    Informant-rated EQ-5D index score.
    Informant/care partner’s own self-reported EQ-5D index score.
    Caregiver burden measures.
    End point primario: Variazione rispetto al basale del punteggio CDR-SB alla Settimana 78.
    Gli endpoint per il periodo di estensione a lungo termine (Long-Term Extension, LTE) sono:
    Incidenza di Eventi Avversi e Eventi Avversi Seri; risultati nell'MRI cerebrale (inclusa l'incidenza di ARIA-E ed ARIA-H); e l'incidenza di anticorpi anti-aducanumab nel siero nel periodo controllato da placebo e nel periodo di estensione
    Variazione delle seguenti misure nei periodi controllati con placebo e LTE dello studio:
    Punteggio CDR - SB .
    Punteggio MMSE .
    Punteggio ADAS - Cog 13.
    Punteggio ADCS - ADL - MCI .
    Segnale amiloide PET ( in un sottogruppo di soggetti) .
    Il volume totale del cervello , il volume dell'ippocampo , il volume ventricolare , e il volume della materia grigia corticale misurato con la risonanza magnetica .
    Connettività funzionale come misurato dal tf - fMRI ( dove disponibile) .
    Il flusso ematico cerebrale come misurato da ASL- RM ( dove disponibile) .
    Livelli di biomarker di malattia correlati al CSF che comprenderanno , ma non sono limitati a , amiloide e proteine ​​tau ( in un sottogruppo di soggetti).
    Livelli di biomarker nel sangue correlati alla malattia che possono includere, ma non sono limitati a, amiloide e proteine ​​tau (in un sottogruppo di soggetti).
    NPI - 10 punteggio totale
    Punteggio EQ-5D dell'informatore.
    Punteggio EQ-5D del partner dell' Informatore/assistente .
    Misura dell'onere dell'informatore/assistente.

    E.5.1.1Timepoint(s) of evaluation of this end point
    Primary endpoint:
    Week 78

    LTE endpoints:
    On-going over the course of the study
    Endopoint primario:
    settimana 78

    Endpoint LTE:
    continuo durante il corso dello studio
    E.5.2Secondary end point(s)
    Change from baseline in MMSE score at Week 78.
    Change from baseline in ADAS-Cog 13 score at Week 78.
    Change from baseline in ADCS-ADL-MCI score at Week 78.
    Variazione dal basale nel punteggio di MMSE alla Settimana 78
    Variazione dal basale nel punteggio di ADAS-Cog 13 alla Settimana 78
    Variazione dal basale nel punteggio di ADCS-ADL-MCI alla Settimana 78
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 78
    Settimana 78
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    evaluation of biomarkers for AD
    Valutazione dei Biomarcatori per AD
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA62
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Czech Republic
    Korea, Republic of
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Ultima Visita ultimo paziente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 600
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 750
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    At the start of the study, subjects must be capable of giving consent personally, however, in the LTE, subjects whose MMSE score is still >15 will be eligible and these subjects will need legal representative to provide consent
    All'inizio dello studio, i soggetti devono essere in grado di dare personalmente il consenso, tuttavia, nel periodo LTE, i soggetti con un punteggio MMSE>15 saranno eleggibili e avranno bisogno di un rappresentante legale per dare il consenso.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state69
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 521
    F.4.2.2In the whole clinical trial 1350
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No further provisions are made for access to the study treatment. Patients will revert to most appropriate standard of care. If aducanumab is proven to be beneficial, all regulatory requirements regarding poststudy access will be met
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation TrialNetworks
    G.4.3.4Network Country United States
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-08-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-09-10
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice